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ABSTRACT 
 
Synthetic cannabinoids (SC) are a large group of chemical compounds that interact 
with the endocannabinoid system with the purpose of producing similar effects to the 
natural Cannabis products. However, they present more serious and unpredictable side 
effects, having a strong connection to the onset of acute psychosis in previously healthy 
individuals, to dependence and abstinence syndrome, and also to serious medical 
problems due to the inexistence of a specific treatment, which may culminate in death. 
Their identification in biological samples is carried out by complex processes only 
accessible in some laboratories, not being detected in routine toxicological tests 
accessible in medical facilities. This work aimed to review the current literature related 
to this subject as a way of better understanding these substances, their effects and how 
hard is to diagnose and consequently treat an acute intoxication in an ER. In the near 
future, it is necessary to develop an effective screening test to use in any ER, improve the 
legislation related to these substances and also discourage their consumption. 
 
Keywords: synthetic cannabinoids; legal highs; spice; cannabinoid receptors; psychosis; 
adverse effects.  
 
 
INTRODUCTION 
 
Synthetic cannabinoids (SC), also known as Spice, K2, among many others, have 
gained popularity since 2004, when they emerged as a new type of recreational drug for 
their psychostimulant properties, along with several other substances, commonly known 
as “legal highs” being attractive for their low cost and easy access through the internet or 
“smart shops” (Seely et al., 2012). These are lab produced cannabinoid receptors agonists, 
originally developed in the 60s to study the pharmacological effects related to activation 
of this type of receptors (Pertwee, 2006). As SC began to be used as clandestinely 
produced recreational drugs , they appeared in the form of smoking herbal blends, 
advertised as incense/potpourri and not appropriate for human consumption (Seely et al., 
2011). 
However, the dried plants present in these blends have no psychotropic effect in most 
cases, just giving the illusion of being of natural origin, being no more than mere vehicles 
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for the SC initially dissolved in a solvent such as acetone or ethanol. This solvent 
subsequently evaporates while SC stay attached to the plants, often in very different 
concentrations within the same package (originating parts where the concentration of SC 
is very high, called “hot spots”) (Fattore and Fratta, 2011; Vandrey et al., 2012). 
The unpredictable toxicity of these drugs, when compared to natural Cannabis does 
not only depend of these so called “hot spots”. In addition to this, the constant change in 
the SC types that happen in order for these products to be kept just outside the law, the 
presence of more than one type of SC in each herbal blend as well as the addition of other 
substances (such as drugs, rat poison or embalming products) all lead to the fact that even 
the most experienced user does not know what is consuming, often with disastrous 
consequences (Dresen et al., 2010; Fattore and Fratta, 2011; National Institute on Drug 
Abuse, 2016). Indeed, beyond the desired euphoria effect, these compounds may cause 
severe psychological and physical adverse effects and even death (Tait et al., 2016). Low 
socioeconomic status may favor the abuse of SC (Joseph et al., 2016). 
This article aims to review the state-of-the-art literature about SC, particularly its 
chemical structure and presentation forms, pharmacokinetics and pharmacodynamics, 
detection and management of acute intoxication. 
 
 
METHODS 
 
An exhaustive literature search was carried out in PubMed (U.S. National Library of 
Medicine), without a limiting period, to identify relevant articles. “Synthetic 
Cannabinoids” and “Cannabimimetics” were used as search keywords . Furthermore, 
electronic copies of the full papers were obtained from the retrieved journal articles as 
well as governmental, European committees’ and UN documents and then further 
reviewed to find possible additional publications related to synthetic cannabinoids. 
 
 
CHEMICAL STRUCTURE AND PRESENTATION FORMS 
 
SC are a large group of compounds (over 160 have been identified) with similar 
action to Δ9-tetrahydrocannabinol (Δ9-THC) molecule, though many of them being more 
potent than Δ9-THC because they are full agonists of cannabinoid receptors, while Δ9-
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THC is partial agonist. Thus, SC present greater affinity and longer retention time to the 
receptors (Castaneto et al., 2014; EMCDDA, 2015). 
Their naming is difficult to understand, often being assigned an abbreviation of the 
person who identified them at first, such as JWH compounds named after John W. 
Hoffman, or the place where they were discovered, as HU compounds which were 
discovered at the Hebrew University or even according to their chemical structure, as 
APICA, deriving from its long chemical name N-(1-adamantyl)-1-pentyl-1H-indole-3-
carboxamide (Table 1) (EMCDDA, 2015; 2016; Seely et al., 2012). 
Most SC are lipophilic, nonpolar and consist of about 20-26 carbon atoms, which 
makes them volatile when smoked with a side chain of 4-9 saturated carbon atoms being 
a common finding in these compounds (Figure 1) (EMCDDA, 2015). 
The smoking herbal blends containing SC are sold in aluminum foil sachets with 
appealing images and exotic names, containing about 3g of dried herbs sprayed with the 
active substances (Johnson et al., 2011). As already mentioned, the active substances of 
these blends are always changing according to the law (Brents and Prather, 2014). If in 
the beginning JWH-018, JWH-073 and CP-47 were the most identified compounds, their 
prohibition in many countries has encouraged the creation of new compounds through 
small molecular changes, with the disappearance of the former SC (Hudson and Ramsey, 
2011). 
 
 
PHARMACOKINETICS 
 
After being smoked (their main administration form) SC reach peak blood 
concentration very quickly, then being redistributed to other tissues such as the brain, as 
demonstrated by a human study in which two individuals smoked 50µg/kg of JWH-018, 
reaching a blood peak concentration of 10µg after 5 minutes then quickly decreasing in 
the following 3h, becoming barely traceable after 24 hours (Teske et al., 2010).  
It was shown that SC undergoes oxidation by cytochrome P450 enzymes (CYP) to 
several hydroxyl metabolites in humans, with intestinal CYP2C9 being very important 
when they were orally ingested, while CYP1A2 was the most abundantly expressed 
enzyme in the lungs, being the main form when CS are smoked (Figure 2) (Chimalakonda 
et al., 2012; Fantegrossi et al., 2014). Another P450 isoform, CYP2D6 also appeared to 
demonstrate an important role by being very active in brain areas with high expression of 
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CB1 receptor, possibly responsible for the SC concentrations in the brain (Fantegrossi et 
al., 2014).  
Metabolites are mostly excreted in the urine (with a small part excreted in the feces) 
and the presence of high urinary levels of SC glucuronide metabolites shows that the final 
metabolic process is the conjugation with glucuronic acid. UDP-glucuronosyltransferase 
enzymes (UGT), namely UGT1A3 and UGT2B7 are the most important enzymes to the 
presence of these final SC metabolites in the urine, with them possibly also being relevant 
for SC concentrations in the brain as it was hypothesized for CYP2D6 (Chimalakonda et 
al., 2012; Fantegrossi et al., 2014). 
It has also been shown that certain SC, like AM-2201, are metabolized originating 
other known compounds such as JWH-018 and JWH-073, which has made difficult task 
of the identification of the initially consumed compound even more challenging, as we 
shall see ahead (Jang et al., 2014). 
 
 
PHARMACODYNAMICS 
 
SC are high affinity full agonists of the cannabinoid receptors 1 and 2, while Δ9-THC 
of natural Cannabis is just a partial agonist (Castaneto et al., 2014). Both are G protein-
coupled receptors, whose stimulation result in neuronal hyperpolarization and decreased 
neurotransmitter release, and are mostly expressed in the central nervous system such as 
cerebral cortex, hippocampus, basal ganglia, cerebellum and hypothalamus, even though 
also being present in many other tissues (Ameri, 1999; Castaneto et al., 2014; Pertwee, 
1997). CB1 receptors are responsible for the psychotropic effects of these, commonly 
known as cannabinoid tetrad (hypothermia, analgesia, catalepsy and locomotor deletion), 
also appearing in the peripheral nervous system (Castaneto et al., 2014; Mechoulam and 
Parker, 2013; Pertwee, 1997). There is not much knowledge regarding CB2 receptors but 
it is known that they are predominantly expressed in lymphoid organs and cells of the 
immune system, with their stimulation having immunomodulatory effects (Pertwee, 
1997). 
However, it still remains unclear why SC have such distinct adverse effects from 
natural Cannabis. One hypothesis is that several of their metabolites continue to show 
high affinity and activation capacity of the receptors, unlike Δ9-THC (Fantegrossi et al., 
2014; Rajasekaran et al., 2013). Another one is that they can act on different receptors, as 
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demonstrated by a study in which SC CP-55,940 increased responsiveness and expression 
of serotoninergic receptor 5-HT2A, which may explain the higher anxiogenic and 
hallucinogenic potential of these substances, since the same mechanism occurs when 
some psychedelic drugs are used, such as LSD (Chiu et al., 2014; Franklin and Carrasco, 
2013). 
Symptoms arising from the use of SC can range from a few minutes to several days, 
in more extreme cases (Berry-Caban et al., 2013; Spaderna et al., 2013; Winstock and 
Barratt, 2013). In addition to the euphoric effect by which these substances are pursued, 
less desirable adverse effects may arise, such as chest pain, tachycardia, hypertension, 
agitation, nausea, emesis, weakness or, in more severe cases, cardiac arrhythmias, 
myocardial infarction, acute renal failure, respiratory depression, flaccid paralysis, 
rhabdomyolysis, seizures and even death cases are described as resulting from the direct 
action of SC (Heath et al., 2012; Lisi, 2014; National Institute on Drug Abuse, 2016; 
Patton et al., 2013; Tait et al., 2016). Although death may occur as a result of intoxication 
by SC, as it was shown by two different case reports on which the main event that led to 
the passing of the two young mans was cardiac arrest shortly after smoking MDMB-
CHMICA, the most common side effects reported are tachycardia, agitation and nausea 
(Adamowicz, 2016; Tait et al., 2016; Westin et al., 2016). 
One of the main problems regarding the use of these drugs is its strong link to the 
risk of developing acute psychosis with hallucinations and schizophrenia, not only in 
predisposed individuals but also in previously healthy individuals (Every-Palmer, 2011; 
Fattore, 2016; Forrester et al., 2012; Oluwabusi et al., 2012). One explanation for these 
events being considerably more common with SC than Cannabis is the fact that these not 
present cannabidiol (CBD), which is thought to be a psychosis-protector molecule, in 
their composition unlike Cannabis and that makes the proven interaction between 
cannabinoids and dopaminergic pathways with their stimulation stronger than with 
Cannabis, possibly contributing to this increased chance of psychosis (Kuepper et al., 
2013; Leweke et al., 2012). 
Acute ischemic stroke was reported in two young women who developed facial and 
hemibody weakness after smoking “K2”. A 32 year old woman had repeated thrombosis 
(two kidney infarcts, pulmonary emboli and an ischemic stroke over 9 months) that only 
stopped when she quit smoking SC.  Another case was one of a 31 year old woman who 
developed toxic leucoencephalopathy after repeatedly inhaling “Buzz Juice” over two 
days (Bernson-Leung et al., 2014; Kak et al., 2016; Raheemullah and Laurence, 2016).  
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There is evidence pointing to the development of tolerance and abstinence after the 
consumption of SC, as demonstrated by a study, in which a young man consuming “Spice 
Gold” continuously for 8 months, in order to feel the same effects, was increasing his 
daily dose up to 3g per day (Zimmermann et al., 2009). The same young man, when 
appealed to the doctor due to adverse effects, ceased consumption and quickly developed 
drug cravings, diaphoresis, hypertension, headache, agitation and nightmares 
(Zimmermann et al., 2009). 
 
 
TOXICOLOGICAL ANALYSIS 
 
Given the increased number emergency room presentations related to SC 
intoxications there always was an urge to find a quick and easy method of identifying 
these compounds or their metabolites, especially in biological samples such as hair, 
blood, saliva or urine, even though that at the moment the available toxicological screens 
in hospitals are still not able to detect them (Dresen et al., 2010; Hudson and Ramsey, 
2011). 
The detection itself is done only in a few laboratories and by complex processes such 
as liquid chromatography mass spectrometry (LC-MS/MS), gas chromatography mass 
spectrometry (GC/MS), matrix-assisted laser absorption / ionization time of flight mass 
spectroscopy (MALDI-TOF), direct analysis in real spectrometry time (DART-MS) or 
immunoassays, not being relevant in clinical decision making due to their duration 
(Castaneto et al., 2015; EMCDDA, 2015; Znaleziona et al., 2015). 
In an autopsy of a 41-year-old woman who quickly died of coronary arterial 
thrombosis after smoking ‘Mojo’, an SC containing herbal blend, ADB-FUBINACA was 
the only SC detected in a postmortem blood sample and the cause of death was considered 
a consequence of that consumption. In another case, 5F-PB-22 was found in the 
postmortem iliac blood of an 18-year-old male who was found dead after a night of 
partying with friends, with bilateral pulmonary and abdominal organs congestion being 
observed at autopsy. In both cases, autopsy blood specimens were extracted by a liquid–
liquid extraction at pH 10.2 into a hexane–ethyl acetate mixture and analyzed by LC–
MS-MS method (Behonick et al., 2014; Shanks et al., 2016). 
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TREATMENT OF INTOXICATIONS 
 
There are no specific therapeutics to CS intoxication, being an expectant attitude and 
supportive treatment adopted, very commonly proceeding to volume expansion by 
administration of intravenous fluids, being benzodiazepines also widely used for the 
control of agitation and more severe cases may require intubation and mechanical 
ventilation (Table 2) (Castellanos and Thornton, 2012; Cooper, 2016). Upon acute 
psychosis presentation, antipsychotic drugs may be used (Cooper, 2016). Other 
symptoms may receive a more directed therapy, with rapid resolution of the case most 
times (National Institute on Drug Abuse, 2016). 
 
 
FINAL REMARKS 
 
The low prices, easy access and the false characterization of “legal highs” led to SC 
becoming very desirable and searched drugs mainly by young people. This has become a 
serious problem, in both medical and legal terms. Fortunately, many countries already 
have an aggressive legal approach to the emergence of these substances, making them 
forbidden at the time of their identification. The information dissemination about 
potential adverse effects made by the media, with the presentation real cases also helped 
to cause a lack of interest towards these drugs. In the future, it would be important to 
invest in the development of an easily accessible and fast detection test in all hospitals for 
more effective therapeutic decision-making, as well as the commercialization of a specific 
antidote for these harmful substances. Moreover, further studies are required to clarify 
interactions with other co-consumed substances. Indeed, registered signs and symptoms 
associated with the use of SC may often not result in their exclusive consumption, once 
they are usually used with other substances, such as alcohol, tobacco, Cannabis, ecstasy, 
opioids, cocaine, among others (Vandrey et al., 2012). 
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TABLES 
Table 1 – Classification of sythetic cannabinoids into 7 groups (EMCDDA, 2015). 
Groups Examples 
Naphthoylindoles JWH-018 and JWH-073 
Naphthylmethylindoles JWH-175 
Naphthoylpyrroles JWH-130 
Naphthylmethylindenes JWH-176 
Phenylacetylindoles JWH-250 
Cyclohexylphenols CP 47.497 
Classical Cannabinoids HU-210 
 
Table 2 – Major averse effects of synthetic cannabinoids and treatment. 
Adverse Events Treatment 
Psychosis, agitation, 
anxiety, paranoia 
Benzodiazepines, antipsychotics, electrolyte 
replacement 
Acute kidney injury Intravenous fluid administration, dialysis 
Tachycardia Negative chronotropic agents, benzodiazepines 
Myocardial infarction Standard treatments, benzodiazepines 
Seizures Benzodiazepines, antiepileptic drugs 
Hyperemesis Hot showers, antiemetics, electrolyte/fluid 
replacement 
 
FIGURES 
             
           JWH-015             JWH-018             JWH-122             JWH-250 
                                                    
           5F-PB-22                              AM-694                               RCS-4                                          HU-210 
 
Figure 1 – Chemical structures of synthetic cannabinoids.  
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Figure 2 – Metabolic pathways for synthetic cannabinoids JWH-018, JWH-073, JWH-
122, MAM-2201, PB-22 and 5F-PB-22. Ester hydrolysis of PB-22 and 5F-PB-22 produce 
1-pentyl-1 H -indole-3-carboxylic acid (PI-COOH) and 5F-PI-COOH, respectively. 
Reproduced from (Castaneto et al., 2015). 
PB-22 5F-PB-22
PB-22-N-5-OH-pentyl
PB-22-N-pentanoic acid
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identification of hairs and fibres), serology, odontology, psychiatry, anthropology, the physical
sciences, firearms, and document examination, as well as investigations of value to public health in its
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The journal publishes:Original Research Papers (Regular Papers) Review Articles Rapid
Communications Technical Notes Forensic Anthropology Population Data Case Reports Preliminary
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AUDIENCE
.
Pathologists, Anthropologists, Psychiatrists, Biologists, Serologists, Odontologists, Physical Scientists,
Toxicologists, Scientists in Legal and Social Medicine, Questioned Documents and Jurisprudence
IMPACT FACTOR
.
2015: 1.950 © Thomson Reuters Journal Citation Reports 2016
AUTHOR INFORMATION PACK 17 Mar 2017 www.elsevier.com/locate/forsciint 2
ABSTRACTING AND INDEXING
.
Bulletin Signalétique
Cambridge Scientific Abstracts
Chemical Abstracts
Criminology, Penology and Police Science Abstracts
Current Contents
MEDLINE®
EMBASE
National Criminal Justice Reference Service
Science Citation Index
Biological Abstracts
Current Awareness in Biological Sciences
Scopus
EDITORIAL BOARD
.
Co Editors-in-Chief
C. Cattaneo, Dipart. di Scienze Biomediche per la Salute, Sezione di Medicina Legale, Università degli Studi di
Milano, via L. Mangiagalli 37, 20133, Milano, Italy
C. Jackowski, Institute of Forensic Medicine, Universität Bern, Bühlstr. 20, CH 3012, Bern, Switzerland
Consulting Editor-in-Chief
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Université de Lausanne, bâtiment BCH, 1015 Lausanne, Switzerland
S. Matuszewski, (for: Forensic Entomology), Adam Mickiewicz University of Poznan, Św. Marcin 90, Poznań,
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GUIDE FOR AUTHORS
.
Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to
submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when
your paper is at the revision stage, will you be requested to put your paper in to a 'correct format'
for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.
INTRODUCTION
Forensic Science International is a peer-reviewed, international journal for the publication of original
contributions in the many different scientific disciplines comprising the forensic sciences. These
fields include, but are not limited to, forensic pathology and histochemistry, toxicology (including
drugs, alcohol, etc.), serology, chemistry, biochemistry, biology (including the identification of hairs
and fibres), odontology, psychiatry, anthropology, the physical sciences, firearms, and document
examination, as well as the many other disciplines where science and medicine interact with the law.
Types of paper
1. Original Research Articles (Regular Papers)
2. Review Articles
3. Rapid Communications
4. Technical Notes
5. Forensic Anthropology Population Data
6. Case Reports
7. Preliminary Communications
8.Letters to the Editor
9. Book Reviews
Please note that all contributions of type 4 to 7 will be published as e-only articles. Their citation
details, including e-page numbers, will continue to be listed in the relevant print issue of the journal's
Table of Contents.
Announcement of Population Data: these types of articles will be published in Forensic Science
International: Genetics, only. Please submit these articles via http://www.ees.elsevier.com/fsigen/.
Preliminary Communications(where brief accounts of important new work may be announced with
less delay than is inevitable with major papers) may be accepted after correspondence with the
appropriate Associate Editor.
Review Articles may be regularly submitted or invited by Editors. However, they will undergo the
normal review process of the journal.
Forensic Anthropology Population Data: Although the main focus of the anthropology section of
the journal remains on the publication of original research, authors are invited to submit their forensic
anthropology population data articles by selecting the "Forensic Anthropology Population Data" article
type on the online submission system. When submitting a Forensic Anthropology Population data
article, please assure that "Forensic Anthropology Population Data" is included as one of the keywords.
These forensic anthropology population data articles involve the application of already published and
standardised methods of aging, sexing, determination of ancestry and stature and other well known
diagnoses on different populations. This is at the heart of applied forensic anthropology. For example,
in order to correctly assess age, stature or even sex of individuals of different ancestry or from
different populations, it is fundamental that the method be tested on the specific population one is
working on. In building the biological profile of a skeleton in order to aid identification, one needs to
calibrate such techniques on the population of interest before applying them. The same may be true
in a completely different scenario of anthropology, for example identifying criminals taped on video
surveillance systems and aging victims of juvenile pornography. This section is dedicated to forensic
anthropological population data and other types of updates (state of the art of particular issues, etc.),
particularly concerning the following:
- Sexing
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- Aging sub adult skeletal remains
- Aging adult skeletal remains
- Aging living sub adults and adults
- Determining ancestry
- Stature estimation
- Facial reconstruction
- Non metric trait distribution, pathology and trauma
- Positive identification of human skeletal remains
- Positive identification of the living
Forensic Anthropology Population Data articles will be published in abridged form in print (a clear,
descriptive summary taken from the abstract), and the full length article will be published online only.
Full citation details and a reference to the online article, including e-page numbers, will be published
in the relevant print issue of the journal. All submitted manuscripts will be evaluated by a strict peer
review process.
Case Reports will be accepted only if they contain some important new information for the readers.
Rapid Communications should describe work of significant interest, whose impact would suffer
if publication were not expedited. They should not be longer than 5 printed journal pages (about
10 submitted pages). Authors may suggest that their work is treated as a Rapid Communication,
but the final decision on whether it is suitable as such will be taken by the handling Editor. Rapid
Communications requiring revision should be resubmitted as a new submission.
Technical Notes report new developments, significant advances and novel aspects of experimental
and theoretical methods and techniques which are relevant for scientific investigations within the
journal scope. Manuscripts of this type should be short (a few pages only). Highly detailed and specific
technical information such as computer programme code or user manuals can be included as electronic
supplements. The manuscript title must start with "Technical Note:".
Revisions deadline
Please note that articles that are sent to the author for revision need to be returned within 60 days
(and within 20 days for subsequent revisions). A reminder will be sent in the second month. Any
articles that are sent after the two month period of revision will be considered a re-submission.
Contact details for submission
Papers for consideration should be submitted by topic. Editors and their topic specialty are listed
below.
C. Cattaneo (Co Editors-in-Chief):
Tel: +39 02503 15679
E-mail: cristina.cattaneo@unimi.it
C. Jackowski (Co Editors-in-Chief):
Tel: +41 (0)31 631 84 12
E-mail: Christian.Jackowski@irm.unibe.ch
A. Carracedo: Forensic Genetics. Please note only review articles on this topic should be submitted
to FSI. All non-review papers should be submitted to the FSI daughter journal devoted to this subject
Forensic Science International: Genetics, via http://ees.elsevier.com/fsigen/
Fax:+34 981 580336
E-mail: angel.carrafsi@usc.es
P. Margot: Questioned Documents and Physical Science: ballistics, tool marks, contact traces, drugs
analysis, fingerprints and identification, etc.
Tel: +41 21 692 4605
Fax: +41 21 692 4605
E-mail: pierre.margot@unil.ch
O.H. Drummer: Toxicology
Tel: +61 3 9684 4334
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Fax: +61 3 9682 7353
E-mail: olaf.drummer@vifm.org
S. Matuszewski: Entomology
Tel: +48 61 82 94 292
E-Mail: szymmat@amu.edu.pl
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for
review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)
Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
• Relevant declarations of interest have been made
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements
For further information, visit our Support Center.
BEFORE YOU BEGIN
Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
Declaration of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial,
personal or other relationships with other people or organizations within three years of beginning the
submitted work that could inappropriately influence, or be perceived to influence, their work. More
information.
Additional information
Multiple submissions is not acceptable to the Editor, and any such papers, together with future
submissions from the authors, will be rejected outright. Submission also implies that all authors have
approved the paper for release and are in agreement with its content.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except
in the form of an abstract or as part of a published lecture or academic thesis or as an electronic
preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more
information), that it is not under consideration for publication elsewhere, that its publication is
approved by all authors and tacitly or explicitly by the responsible authorities where the work was
carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or
in any other language, including electronically without the written consent of the copyright-holder. To
verify originality, your article may be checked by the originality detection service CrossCheck.
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Contributors
Each author is required to declare his or her individual contribution to the article: all authors must have
materially participated in the research and/or article preparation, so roles for all authors should be
described. The statement that all authors have approved the final article should be true and included
in the disclosure.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their
manuscript and provide the definitive list of authors at the time of the original submission. Any
addition, deletion or rearrangement of author names in the authorship list should be made only
before the manuscript has been accepted and only if approved by the journal Editor. To request such
a change, the Editor must receive the following from the corresponding author: (a) the reason
for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they
agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of
authors after the manuscript has been accepted. While the Editor considers the request, publication
of the manuscript will be suspended. If the manuscript has already been published in an online issue,
any requests approved by the Editor will result in a corrigendum.
Article transfer service
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is
more suitable in one of our other participating journals, then you may be asked to consider transferring
the article to one of those. If you agree, your article will be transferred automatically on your behalf
with no need to reformat. Please note that your article will be reviewed again by the new journal.
More information.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see
more information on this). An e-mail will be sent to the corresponding author confirming receipt of
the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version
of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations. If
excerpts from other copyrighted works are included, the author(s) must obtain written permission
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for
use by authors in these cases.
For open access articles: Upon acceptance of an article, authors will be asked to complete an
'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles
is determined by the author's choice of user license.
Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More
information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement then this should
be stated.
Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply
with their funder's open access policies. Some funding bodies will reimburse the author for the Open
Access Publication Fee. Details of existing agreements are available online.
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After acceptance, open access papers will be published under a noncommercial license. For authors
requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.
Open access
This journal offers authors a choice in publishing their research:
Open access
• Articles are freely available to both subscribers and the wider public with permitted reuse.
• An open access publication fee is payable by authors or on their behalf, e.g. by their research funder
or institution.
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through
our universal access programs.
• No open access publication fee payable by authors.
Regardless of how you choose to publish your article, the journal will apply the same peer review
criteria and acceptance standards.
For open access articles, permitted third party (re)use is defined by the following Creative Commons
user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective
work (such as an anthology), as long as they credit the author(s) and provided they do not alter or
modify the article.
The open access publication fee for this journal is USD 2500, excluding taxes. Learn more about
Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of
green open access options available. We recommend authors see our green open access page for
further information. Authors can also self-archive their manuscripts immediately and enable public
access from their institution's repository after an embargo period. This is the version that has been
accepted for publication and which typically includes author-incorporated changes suggested during
submission, peer review and in editor-author communications. Embargo period: For subscription
articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers
before an article becomes freely available to the public. This is the embargo period and it begins from
the date the article is formally published online in its final and fully citable form. Find out more.
This journal has an embargo period of 12 months.
Elsevier Publishing Campus
The Elsevier Publishing Campus (www.publishingcampus.com) is an online platform offering free
lectures, interactive training and professional advice to support you in publishing your research. The
College of Skills training offers modules on how to prepare, write and structure your article and
explains how editors will look at your paper when it is submitted for publication. Use these resources,
and more, to ensure that your submission will be the best that you can make it.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of
these). Authors who feel their English language manuscript may require editing to eliminate possible
grammatical or spelling errors and to conform to correct scientific English may wish to use the English
Language Editing service available from Elsevier's WebShop.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/fsi.
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PREPARATION
NEW SUBMISSIONS
Submission to this journal proceeds totally online and you will be guided stepwise through the creation
and uploading of your files. The system automatically converts your files to a single PDF file, which
is used in the peer-review process.
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file
to be used in the refereeing process. This can be a PDF file or a Word document, in any format or lay-
out that can be used by referees to evaluate your manuscript. It should contain high enough quality
figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at
the initial submission. Please note that individual figure files larger than 10 MB must be uploaded
separately.
References
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct.
Formatting requirements
There are no strict formatting requirements but all manuscripts must contain the essential elements
needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and
Methods, Results, Conclusions, Artwork and Tables with Captions.
If your article includes any Videos and/or other Supplementary material, this should be included in
your initial submission for peer review purposes.
Divide the article into clearly defined sections.
Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text
in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should
be placed directly below the figure or table.
Double-blind review
This journal uses double-blind review, which means the identities of the authors are concealed from
the reviewers, and vice versa. More information is available on our website. To facilitate this, please
include the following separately:
Title page (with author details): This should include the title, authors' names and affiliations, and a
complete address for the corresponding author including an e-mail address.
Blinded manuscript (no author details): The main body of the paper (including the references,
figures, tables and any acknowledgements) should not include any identifying information, such as
the authors' names or affiliations.
REVISED SUBMISSIONS
Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an
editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting
codes will be removed and replaced on processing the article. The electronic text should be prepared
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with
Elsevier). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your word processor.
Article structure
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Results
Results should be clear and concise.
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Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s)
of each author and check that all names are accurately spelled. Present the authors' affiliation
addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-
case superscript letter immediately after the author's name and in front of the appropriate address.
Provide the full postal address of each affiliation, including the country name and, if available, the
e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing
and publication, also post-publication. Ensure that the e-mail address is given and that contact
details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually did the work must be
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the
research, the principal results and major conclusions. An abstract is often presented separately from
the article, so it must be able to stand alone. For this reason, References should be avoided, but if
essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should
be avoided, but if essential they must be defined at their first mention in the abstract itself.
Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online
article. The graphical abstract should summarize the contents of the article in a concise, pictorial form
designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a
separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 ×
13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office
files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best
presentation of their images and in accordance with all technical requirements: Illustration Service.
Highlights
Highlights are mandatory for this journal. They consist of a short collection of bullet points that
convey the core findings of the article and should be submitted in a separate editable file in the
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points
(maximum 85 characters, including spaces, per bullet point). You can view example Highlights on
our information site.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and
avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing
with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords
will be used for indexing purposes.
Acknowledgements
Please provide Acknowledgements as a separate file and remove this from the manuscript. List
here those individuals who provided help during the research (e.g., providing language help, writing
assistance or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:
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Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes
of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When
funding is from a block grant or other resources available to a university, college, or other research
institution, submit the name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors.
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word
processors build footnotes into the text, and this feature may be used. Should this not be the case,
indicate the position of footnotes in the text and present the footnotes themselves separately at the
end of the article.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a
single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi
is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. Further information on the preparation of
electronic artwork.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but
explain all symbols and abbreviations used.
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Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules and shading in table cells.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
A DOI can be used to cite and link to electronic articles where an article is in-press and full citation
details are not yet known, but the article is available online. A DOI is guaranteed never to change,
so you can use it as a permanent link to any electronic article. An example of a citation using DOI
for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M.
(2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal
of Geophysical Research, http://dx.doi.org/10.1029/2001JB000884i. Please note the format of such
citations should be in the same style as all other references in the paper.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them
in your text and including a data reference in your Reference List. Data references should include the
following elements: author name(s), dataset title, data repository, version (where available), year,
and global persistent identifier. Add [dataset] immediately before the reference so we can properly
identify it as a data reference. The [dataset] identifier will not appear in your published article.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference
management software products. These include all products that support Citation Style Language
styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/forensic-science-international
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book
title, chapter title/article title, year of publication, volume number/book chapter and the pagination
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted
at proof stage for the author to correct. If you do wish to format the references yourself they should
be arranged according to the following examples:
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Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun.
163 (2010) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z.
Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.
Reference to a website:
[4] Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13.03.03).
Reference to a dataset:
[dataset] [5] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese oak wilt
disease and surrounding forest compositions, Mendeley Data, v1, 2015. http://dx.doi.org/10.17632/
xwj98nb39r.1.
Video
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum size
of 150 MB. Video and animation files supplied will be published online in the electronic version of your
article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can
choose any frame from the video or animation or make a separate image. These will be used instead
of standard icons and will personalize the link to your video data. For more detailed instructions please
visit our video instruction pages. Note: since video and animation cannot be embedded in the print
version of the journal, please provide text for both the electronic and the print version for the portions
of the article that refer to this content.
Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel
or PowerPoint files will appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to
supplementary material during any stage of the process, please make sure to provide an updated file.
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option
in Microsoft Office files as these will appear in the published version.
Data in Brief
You have the option of converting any or all parts of your supplementary or additional raw data into
one or multiple data articles, a new kind of article that houses and describes your data. Data articles
ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly
available to all upon publication. You are encouraged to submit your article for Data in Brief as an
additional item directly alongside the revised version of your manuscript. If your research article is
accepted, your data article will automatically be transferred over to Data in Brief where it will be
editorially reviewed and published in the open access data journal, Data in Brief. Please note an open
access fee is payable for publication in Data in Brief. Full details can be found on the Data in Brief
website. Please use this template to write your Data in Brief.
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AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words
and to help readers understand what the paper is about. More information and examples are
available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.
AFTER ACCEPTANCE
Availability of accepted article
This journal makes articles available online as soon as possible after acceptance. This concerns the
accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset or
proofread. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable
by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it is
an unedited article. Subsequent production stages will simply replace this version.
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author will, at no cost, receive 25 free paper offprints, or alternatively a customized
Share Link providing 50 days free access to the final published version of the article on ScienceDirect.
The Share Link can be used for sharing the article via any communication channel, including email
and social media. For an extra charge, paper offprints can be ordered via the offprint order form which
is sent once the article is accepted for publication. Both corresponding and co-authors may order
offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article
open access do not receive a Share Link as their final published version of the article is available open
access on ScienceDirect and can be shared through the article DOI link.
Author orders
When your article is published, you can commemorate your publication with printed author
copies of the journal issue, customized full-color posters, extra offprints, and more. Please visit
http://webshop.elsevier.com to learn more.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from
Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will
be published.
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